- Profound Medical (PRN) has appointed Kenneth Knudson as its new Chief Commercial Officer
- Mr. Knudson has over 25 years of experience in executive management
- He will lead Profound Medical’s worldwide sales, marketing, and reimbursement activities
- Profound Medical is a commercial-stage medical device company that develops and markets customizable, incision-free therapies
- Shares in Profound Medical Corp. (PRN) are up 5.14 per cent, trading at $14.31 per share
Profound Medical (PRN) has appointed Kenneth Knudson as its new Chief Commercial Officer.
A global medical device industry veteran, Mr. Knudson will lead Profound Medical’s worldwide sales, marketing, and reimbursement activities.
Mr. Knudson has over 25 years of experience in executive management, having worked for both emerging start-ups and Fortune 500 companies.
Most recently, he served as Chief Executive Officer of Perineologic Inc., a company pioneering a new and disruptive approach to prostate cancer biopsy.
Before serving at Perineologic, Mr. Knudson worked as Executive VP of global sales and marketing for Boston Scientific Corporation (BSCI) and Augmenix, where he helped drive annual sales of SpaceOAR™ Hydrogel to over $100 million in just four years.
His early career included progressive sales leadership roles with BSCI’s Urology and Women’s Health Divisions.
“We are thrilled to have Ken join our team,” said Profound Medical CEO Arun Menawat. “His extensive and demonstrable record of accomplishment in helping to commercialize new medical technologies in urology […] will be invaluable as we continue to execute our commercial strategies for TULSA-PRO® and Sonalleve®.”
“It has been captivating to watch the scale, scope and speed with which leading urologists and teaching hospitals have already begun to adopt TULSA-PRO®,” commented Mr. Knudson. “I am incredibly energized by this opportunity to build on that.”
Profound Medical is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
The company is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Shares in Profound Medical Corp. (PRN) are up 5.14 per cent, trading at $14.31 per share as of 3:26 pm EST.
